Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 12/20 | 0.56 |
| ▸ | PTGER4 | P35408 | 7/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4470865 | 0.87 | PTGER4 (0.64) | PTGER4 | |
| SCHEMBL4480347 | 0.80 | F2RL3 (0.67) | PTGER4 | |
| SCHEMBL4476609 | 0.79 | PTGER4 (0.69) | PTGER4 | |
| SCHEMBL4485895 | 0.79 | CYP1A2 (0.49) | PTGER4 | |
| SCHEMBL4494497 | 0.77 | ALDH1A1 (0.53) | PTGER4 | |
| SCHEMBL27688464 | 0.76 | CYP1A2 (0.59) | PTGER4 | |
| SCHEMBL4481481 | 0.75 | PTGER4 (0.55) | HDAC6PTGER4 | |
| SCHEMBL27669290 | 0.74 | L3MBTL1 (0.56) | PTGER4 | |
| SCHEMBL4479319 | 0.73 | SMN1; SMN2 (0.52) | PTGER4 | |
| SCHEMBL20534782 | 0.72 | HDAC6 (1.00) | HDAC6HDAC1HDAC8HDAC10HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100516049-C | Antiangiogenic agent N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles | YUNG SHIN PHARM IND CO LTD (CN) | 2009-07-22 | — | — | CN | disclosed |
| US-7514465-B2 | Synthesis of N2-(substituted arylmethyl)-3-(substituted phenyl)indazoles as novel anti-angiogenic agents | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2009-04-07 | — | — | US | disclosed |
| CN-1962640-A | Novel anti-angiogenic drug N2Synthesis of- (substituted arylmethyl) -3- (substituted phenyl) indazoles | YUNG SHIN PHARM IND CO LTD (CN) | 2007-05-16 | — | — | CN | disclosed |
| EP-1659115-A1 | Synthesis of substituted 2H-indazole derivatives as anti-angiogenic agents | Yung Shin Pharm. Ind. Co., Ltd. (TW) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106032-A1 | Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents | YUNG SHIN PHARM. IND. CO., LTD. (TW) | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106032-A1 | Synthesis of N2 - (substituted arylmethyl) -3- (substituted phenyl) indazoles as novel anti-angiogenic agents | FLT4, FLT1, KDR | HDAC6 366/4885PTGER4 1430/4885HDAC1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.